Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Zhejiang Cancer Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06624878CT.gov Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer | — | Completed | — | — | — |
NCT06431386CT.gov Behavioural Activation Therapy and Esketamine for Resistant Depression | — | Terminated | — | — | — |
NCT05268497CT.gov A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression | — | Withdrawn | — | — | — |
NCT04303325CT.gov Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI) | — | Recruiting | — | — | — |
NCT04425473CT.gov Esketamine and Perioperative Depressive Symptoms | — | Completed | — | — | — |
NCT04850937CT.gov Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer | — | Completed | — | — | — |
NCT04476446CT.gov An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives | — | Completed | — | — | — |
NCT02493868CT.gov A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02422186CT.gov A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02374567CT.gov Pharmacovigilance in Gerontopsychiatric Patients | — | Terminated | — | — | — |
Show 1 more trialShow fewer
NCT03829579CT.gov Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD) | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pregabalin (this asset) | Zhejiang Cancer Hospital | Approved | BB · 71 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Saredutant | Sanofi | P3 | BBB |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Paroxetine | Brigham and Women's Hospital | P4 | BBB |
| Citalopram | Western University, Canada | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Pregabalin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P4 | A · 82 |
| Peripheral Neuropathy | — | P4 | A · 82 |
| Postherpetic Neuralgia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pregabalin in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pregabalin-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →